Retrospective cohort study shows reduced intraocular pressure in glaucoma patients switched to latanoprostene bunod, suggesting a viable treatment option.
In this retrospective cohort of Taiwanese patients with glaucoma whose IOP remained inadequately controlled on prior PGAs therapy, switching to LBN was associated with a statistically significant, although modest, reduction in IOP over 12 months and a low rate of mild, non-serious ocular adverse events. These exploratory real-world findings provide hypothesis-generating evidence supporting LBN as a treatment option when further IOP reduction is needed and should be confirmed in larger prospective multicenter studies.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: